We often get asked what the commercial opportunity for Pixuvri is in the EU. So to assess the market size in addition to our own internal forecast, we engaged Kantar research, who conducted what they call in-market research in the EU among 251 lymphoma specialists in the 5 major market countries, capturing data on their current treatment practices for patients who are third or fourth line who have aggressive B-cell non-Hodgkin's lymphoma, and how those practices would potentially change with the introduction of Pixuvri.
Now it's important to keep in mind, our labeled indication is in the third and fourth line B-cell aggressive NHL. And in that subset of 112 patients, the CR/CRu rate was 28% for Pixuvri versus 4% for comparator, and overall response rate was 48% for Pixuvri compared to 12% for comparative single therapy. And at 2 years of follow up, there was a 50% reduction in the risk of death or relapse, the so-called progression-free survival, with the median overall survival for Pixuvri on being 13.9 months versus 7.8 months for the comparative active chemotherapeutic agent.
So these are the data that we'll focus on with the help and payers -- health authorities and payers when considering the value proposition for Pixuvri in this patient population. And based on Kantar's research, their analyses, including their discounts, we're encouraged by the projected market opportunity for Pixuvri in the EU given the percentage of physicians who noted that they would integrate Pixuvri into their current treatment practices for patients with relapsed aggressive B-cell non-Hodgkin's lymphoma. And we look forward to updating you as we initiate market introduction and begin to get an indication of product demand.
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV